SavedAdd your journal

Journals / SDÜ Tıp Fakültesi Dergisi / 2022 / Cilt: 29 Sayı: 2

WHAT IS EPIGENETIC CHANGE AND WHAT DO WE KNOW ABOUT ITS IMPACT ON MOLECULAR PATHOLOGIC MECHANISMS OF THE DISEASES?

EPİGENETİK DEĞİŞİKLİK NEDİR VE HASTALIKLARIN MOLEKÜLER PATOLOJİK MEKANİZMALARI ÜZERİNDEKİ ETKİSİ HAKKINDA NE BİLİYORUZ?

Kemal Kürşat BOZKURT
Ayca TAN
Onur ERTUNÇ
Rafet Güneş ÖZTÜRK
Yasemin ÇAKIR
Zeynep SAĞNAK YILMAZ
Şadiye ÜNLÜ
Pages
273–283
Publication Date
2022-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to provide information about the mechanisms of epigenetic changes and their role in the development of neoplastic and nonneoplastic diseases, which may be helpful for the clinicians and laboratory medicine experts for further researchs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Epigenetic change refers to a phenotypic alteration without permanent genotypic change, which occurs through chromatin modification, DNA methylation, histone modification, chromatin-regulating proteins and non-coding RNAs.
📊
Key Findings & Data:Post-transcriptional m6A RNA methylation is also a newly described epigenetic mechanism and believed to be a new diagnostic biomarker and potential therapeutic target.
💡
Conclusion & Impact:The aim of this review is to provide information about the mechanisms of epigenetic changes and their role in the development of neoplastic and nonneoplastic diseases, which may be helpful for the clinicians and laboratory medicine experts for further researchs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:epigenetik · hastalık · nonneoplastik

Abstract

Epigenetic change refers to a phenotypic alteration without permanent genotypic change, which occurs through chromatin modification, DNA methylation, histone modification, chromatin-regulating proteins and non-coding RNAs. Post-transcriptional m6A RNA methylation is also a newly described epigenetic mechanism and believed to be a new diagnostic biomarker and potential therapeutic target. It is a well- known fact that epigenetic changes play a significant role in the development and progression of several nonneoplastic and neoplastic diseases. Therefore, epigenetic changes are of value in diagnostic and prognostic terms. On the other hand, with the development of personalized medicine and targeted treatment approaches, treatment strategies targeting the epigenetic changes are becoming a promising area for many diseases. The aim of this review is to provide information about the mechanisms of epigenetic changes and their role in the development of neoplastic and nonneoplastic diseases, which may be helpful for the clinicians and laboratory medicine experts for further researchs.

Özet

Epigenetik değişiklik, kromatin modifikasyonu, DNA metilasyonu, histon modifikasyonu, kromatin düzenleyici proteinler ve kodlamayan RNA'lar yoluyla meydana gelmekte olup, kalıcı genotipik değişiklik olmaksızın gerçekleşen fenotipik bir değişikliği ifade eder. Transkripsiyon sonrası m6A RNA metilasyonu da yeni tanımlanmış bir epigenetik mekanizma olup, yeni bir tanısal biyobelirteç ve potansiyel terapötik hedef olduğuna inanılmaktadır. Epigenetik değişikliklerin birçok nonneoplastik ve neoplastik hastalığın gelişiminde ve ilerlemesinde önemli bir rol oynadığı iyi bilinen bir gerçektir. Bu nedenle epigenetik değişiklikler tanısal ve prognostik açıdan değerlidir. Öte yandan kişiselleştirilmiş tıp ve hedefe yönelik tedavi yaklaşımlarının gelişmesiyle birlikte epigenetik değişiklikleri hedefleyen tedavi stratejileri birçok hastalık için umut verici bir alan haline gelmektedir. Bu derlemenin amacı, epigenetik değişikliklerin mekanizmaları ve neoplastik / nonneoplastik hastalıkların gelişimindeki rolleri hakkında klinisyenlere ve laboratuvar tıbbı uzmanlarına daha sonraki araştırmalar için yardımcı olabilecek bilgiler sağlamaktır.

🔖

Cite This Article

BOZKURT, K. K., TAN, A., ERTUNÇ, O., ÖZTÜRK, R. G., ÇAKIR, Y., YILMAZ, Z. S., ÜNLÜ, Ş. (2022). WHAT IS EPIGENETIC CHANGE AND WHAT DO WE KNOW ABOUT ITS IMPACT ON MOLECULAR PATHOLOGIC MECHANISMS OF THE DISEASES?. SDÜ Tıp Fakültesi Dergisi, Cilt: 29 Sayı: 2, 273–283. https://ajindex.com/articles/912120

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Referans1. Cooper GM (Ed.). The cell: a molecular approach. Eighth edition. Oxford
  2. New York: Sinauer Associates, an imprint of Oxford University Press
  3. ISBN:9781605357461. Referans2. Carlberg C, Molnar F (Eds.). Human Epigenetics: How Science Works. Springer Nature Switzerland
  4. ISBN:978-3-030-22907-8. Referans3. Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh GHT, Wong AHC, Feldcamp LA, Virtanen C, Halfvarson J, Tysk C, McRae AF, Visscher PM, Montgomery GW, Gottesman II, Martin NG, Petronis A. DNA Methylation Profiles in Monozygotic and Dizygotic Twins. Nat Genet 2009
  5. 41(2):240-245. DOI:10.1038/ng.286. Referans4. Zhang Y, Geng X, Li Q, Xu J, Tan Y, Xiao M, Song J, Liu F, Fang C, Wang H. m6A modification in RNA: biogenesis, functions and roles in gliomas. J Exp Clin Cancer Res 2020
  6. DOI:10.1186/s13046-020-01706-8. Referans5. Yang C, Hu Y, Zhou B, Bao Y, Li Z, Gong C, Yang H, Wang S, Xiao Y. The role of m6A modification in physiology and disease. Cell Death Dis 2020
  7. DOI:10.1038/s41419-020-03143-z. Referans6. Burns SN. Gene Expression, Epigenetic Regulation and Cancer. In: Bishnupuri KS, Mishra MK (Eds.). Epigenetic Advancements in Cancer. 1st ed. Cham: Springer International Publishing
  8. ISBN:978-3-319-24951-3. Referans7. Lassi M, Teperino R. Introduction to Epigenetic Inheritance: Definition, Mechanisms, Implications and Relevance. In Teperino R (Ed.). Beyond Our Genes. Pathophysiology of Gene and Environment Interaction and Epigenetic Inheritance. Switzerland: Springer Nature AG, 2020:159-161. ISBN:978-3-030-35213-4. Referans8. Heard E, Martienssen RA. Transgenerational epigenetic inheritance: Myths and mechanisms. Cell 2014
  9. 157(1):95-109. DOI:10.1016/j.cell.2014.02.045. Referans9. Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. Nat Rev Genet 2019
  10. 20(4):207-220. DOI:10.1038/s41576-018-0089-8. Referans10. Murakami Y. Heterochromatin and Euchromatin. In: Encyclopedia of Systems Biology. New York, NY: Springer New York
  11. DOI:10.1007/978-1-4419-9863-7_1413. Referans11. Whalen S, Truty RM, Pollard KS. Enhancer–promoter interactions are encoded by complex genomic signatures on looping chromatin. Nat Genet 2016
  12. 48(5):488-496. DOI:10.1038/ng.3539. Referans12. Calo E, Wysocka J. Modification of Enhancer Chromatin: What, How, and Why? Mol Cell 2013
  13. 49(5):825-837. DOI:10.1016/j.molcel.2013.01.038. Referans13. Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation landscape in ca